19 August 2025
19 August 2025
Shares in the pharma company tumbled 9.5% amid the restructuring.
The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.
Ogsiveo's approval is backed by results from the Phase III DeFi trial.
The agreement provides Santen exclusive rights to develop, manufacture and market RC28-E in multiple territories.
Andrew Wyatt, digitalisation expert at Sapio Sciences, discusses how LIMS is transforming data management and boosting efficiency in tech-driven research and clinical labs.
Precigen’s immunotherapy will likely reduce the need for repeat surgeries in recurrent respiratory papillomatosis (RRP) patients.
The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).
The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
